

Global Leader in Therapeutic Ultrasound

edap tms

Bringing New Horizons to Therapy

Forward Looking Statements

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer or sale of securities may be made only by means of a prospectus and a related prospectus supplement (collectively, the "Prospectus"), which will be filed with the Securities and Exchange Commission.

The presentation is being furnished to you solely for your information, and may not be copied, reproduced, distributed or passed, directly or indirectly, in whole or in part, to any other person.

This presentation includes only summary information and does not purport to be complete. Any information in this presentation is subject to modification at any time and the Company undertakes no obligation to update you, except to the extent required by applicable law. If an offer of securities is made by the Company in the future, prospective investors should rely solely on the Prospectus, including the information incorporated by reference into the Prospectus. No reliance may be placed for any purposes whatsoever on the information contained in this presentation, or on its completeness, accuracy or fairness. It is the responsibility of each prospective investor to review the Prospectus, including the information incorporated by reference and independent assessment of the risks and merits of any such offering.

This presentation contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans and, in particular, the regulatory review process in the United States by the Food and Drug Administration (the "FDA"). Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, any negative decision by the FDA or another regulatory authority and those described in the Company's filings with the Securities and Exchange Commission, including under "Forward-Looking Information", "Risk Factors" and "Operating and Financial Review and Prospects" in the Company's 2016 annual report on Form 20-F filed with the SEC on April 3, 2017.

Investment Highlights

Innovative minimally-invasive diagnostic and therapeutic platform using ultrasound-based technologies

HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) PLATFORM

Tool for minimally invasive soft tissue ablation, currently approved for treatment of prostate cancer

ROBUST HIFU PIPELINE

Huge potential to leverage HIFU platform in endometriosis, liver cancer, pancreatic cancer, and other soft tissue ablation indications

EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY (ESWL)

Portfolio provides multiple solutions for the destruction of kidney and other urinary stones

COMPANY SNAPSHOT

Direct marketing worldwide through 6 subsidiaries (USA, Germany, Italy, Japan, Malaysia, South Korea) and 2 representative offices (Emirates, Russia) 200 total employees 50+ distributors in 50 countries

HIFU Technology


HIFU principles are similar to sun beams going through a magnifying glass

HIFU =

Acoustic pressure or vibrations delivered to targeted cells Intense immediate tissue heating at focal point (+85°C) Creates cavitation i.e. tissue necrosis and cellular ablation


HIFU perfectly address medical needs for tissue ablation while preserving healthy surrounding tissue EDAP's HIFU platform is a robotic device with highly precise mechatronics, providing image guidance with motion tracking and real-time treatment planning

Superior HIFU Expertise + Strong IP Portfolio



HIFU For Prostate Tissue Ablation

+2,9 million men in the U.S. live with prostate cancer



Prostate cancer is the most prevalent male cancer with approx. 700,000 new cases diagnosed annually worldwide

35% of patients undergo Radical Surgery, 45% Radiotherapy (20%-50% considered as "overtreatment" and "overly aggressive") **20-25%** of patients undergo stressful Active Surveillance or "A.S." 1/3 of patients leave A.S. within 1 year for radical treatment; >50% initiate radical treatment within 5 years) **40%** radiation failures: market caption opportunity with HIFU (80% cancer specific survival rate & 79.6% metastasis rate at 5 years)

Strong Clinical Validation

HIFU for Prostate Tissue Ablation

HIGH EFFICACY

98% cancer specific survival at 10 years¹ 95% metastasis free rate at 10 years¹

LOW MORBIDITY


3.3% incontinence¹
65% preservation of erectile function²
(85% with nerve-sparing strategy³)

ALSO AVAILABLE FOR SALVAGE TREATMENT

80% cancer specific survival 79.6% metastasis free rate at 5 years

 ¹ Thuroff et al. J. Urol. 2013 Feb; ² Ganzer et al. - 2013 BJUI [doi:10.1111/j.1464-410X.2012.11715.];
 ³ D'Hont et al. P088 EMUC 2012 ; *Boorjian et al J Urol. 2008 Apr;179(4):1354-60; Stephenson et al J Clin Oncol. 2009 Sep 10;27(<u>26</u>):4300-5

Morbidity Comparison at 2 Years



Definitions:

ProtecT: ED = insufficient for intercourse, Incontinence = pad use AFU: ED = SHIM < 17, Incontinence = pad use FDA: ED = moderate/severe AE reporting, Incontinence = moderate/severe AE reporting

⁴Donovan et al NEJM 2016 ⁵Rischmann et al European Urology 2016 ⁶Sponsor Executive Summary PMA P13003 (www.fda.gov)

Strong Clinical Validation

THE JOURNAL

UROLOGY

HIFU for Prostate Tissue Ablation









EUROPEAN

eau

American

Urological

Association

Ongoing clinical trials designed to improve treatment performance and outcomes



+ 80 peer-reviewed publications



Product Offering & Positionning





	ABLATHERM FUSION HIFU For Prostate Tissue Ablation	FOCAL ONE Premium Device for Focal Therapy in Prostate Ablation
Diagnostic Information	Ultrasound + MRI Imaging	Ultrasound + MRI Imaging
Dynamic Focusing		\checkmark
Mobile Unit	\checkmark	
Targeted Customer	ASC & Small-Medium Hospitals	Large academic institutions
Price Point	\$320K	\$695K

HIFU Platform Pipeline Opportunity: Rectal Endometriosis









Affects approximately one in ten women of reproductive age Current treatment modalities Rectal removal Invasive surgery HIFU treatment similar to prostate cancer treatment, endorectal approach

Clinical timeline

Initiating phase 2 study in 2019 CE mark submission in 2021

AFFECTS 22 MILLION WOMEN GLOBALLY

HIFU Platform Pipeline Opportunity: Liver Cancer

LIVER CANCER

Primary (Hepatocellular Carcinoma): 750,000 cases WW Liver Metastases : 600,000 cases WW

EDAP's HIFU technology addresses liver cancer with an opensurgery approach.

EDAP'S LIVER HIFU PLATFORM ALLOWS FOR


A necrosis of liver metastasis not accessible via surgery A reduction of bleeding risks hence of surgery time A preservation of liver volume

CURRENT STATUS OF THE DEVELOPMENT PROGRAM:

Phase I (single-center) Study: Feasibility and Safety demonstrated, 26 patients treated, study soon finalized

Phase II (multi-center) Study: Efficacy to be demonstrated, 4 Liver HIFU platforms prototypes to be placed in clinical centers (2018-2019)

CE mark submission anticipated in 2022



HIFU Platform – One EDAP HIFU in Each Operating Room

Diagnostic and Therapeutic Tool for Every OR to Serve Multiple Soft Tissue Ablation Indications

Pursuing numerous specific indications...

- Pancreatic Cancer
 - Pre-clinical trials ongoing
 - Phase 1 study to be initiated in 2021
- Breast Cancer
 - Pre-clinical trials ongoing
- Gynecology
 - Treatment of placenta accrete
 - Pre-clinical trials to be initiated

...But ultimately a platform for broad applications

- ➢ "EDAP Inside"
 - > HIFU as a useful diagnostic imaging tool
 - HIFU as a valuable therapeutic tool to treat any condition requiring soft tissue ablation

EDAP's HIFU platform will be for soft tissue ablation what multi-purpose robotic systems are to surgery.

Lithotripsy for Treatment of Kidney Stones



Urinary stones are most the prevalent pathology of the urinary tract, affecting 5% to 7% of women and 10% to 12% of men



Lithotripsy provides an alternative to open kidney surgery, which is the the gold standard for most urinary stones



EDAP is one of the world leaders in the field with an installed base of more than 700 lithotripsy devices



Product portfolio: (a) Treatment of urinary stones is a mature market, but it is dynamic and subject to a burgeoning replacement cycle (b) EDAP market share...









ESWL Platform





	Sonolith i-move	Sonolith i-sys
Concept System	Fully Modular	Fully Integrated and Robotized
Unique Patented VT	\checkmark	\checkmark
Exclusive ECL Technology	\checkmark	\checkmark
Targeted Customer	ASC & Partnership Model	Large academic institutions
Price Point	\$250K-\$420k	500K

EDAP Product Categories Summary

HIFU MARKET SIZE	LITHOTRIPSY
 Prostate Cancer > 700,000 new annual cases worldwide > +165,000 new cases / year in the U.S. > +2,9 million men in the U.S. live with prostate cancer 	Stable Market Opportunity for Urinary Stones➤ Affects 10-12% of men and 5-7% of women
 Rectal Endometriosis ➢ 22 million women worldwide ➢ CE mark submission in 2021 	 Market Leading Technology Via Multiple Techniques Electroconductive versus Piezoelectric
 Liver Cancer ➢ 600,000 liver metastasis patients worldwide ➢ CE mark submission in 2022 	 Complete Stone Management > Offering both fully-integrated and modular systems
 The potential for HIFU Ablation of Soft Tissue Diagnostic and therapeutic tool for every operating room Current focus on liver and pancreatic cancer, and endometriosis 	Solid Replacement Cycle Opportunity ➤ Modular offering may drive upgrade activity

Experienced Management Team

Executive	Title	Years at EDAP	Previous Experience
Marc Oczachowski	Chief Executive Officer	20	SODEM SYSTEMS
Francois Dietsch	Chief Financial Officer	13	Valeo
Emmanuel Blanc	Chief Technology Officer	29	
Hugo Embert	Chief Marketing Officer	10	CYNOVAD CYBERNETIC INNOVATIONS FOR DENTISTRY
Emmanuel Carre	VP, Industrial Operations	14	Our Passion. Your Advantage.

Key Financial Data

Revenue Growth

	Nine Months Ended September 30,		Twelve Months Ended December 31,	
(in €Millions except per share data)	2018	2017	2017	2016
Revenue	€25.9	€25.1	€35.7	€35.6
Gross Profit	10,9	10.4	14.8	16.4
Gross Margin	42.3%	41.4%	41.4%	46.1%
Operating Profit (Loss)	(2.2)	(1.8)	(2.0)	0.4
Net Income (Loss)	(1.4)	(0.6)	(0.7)	3.8
Earnings (Loss) Per Share	(0.05)	(0.02)	(0.02)	0.13



Balance Sheet Highlights

	Balance Sheet As Of:		
(in €Millions)	September 30, 2018	December 31, 2017	December 31, 2016
Cash & Cash Equivalents	€ 15.9	€ 20.0	€ 22.0
Total Assets (excl. Cash)	8.2	7.2	5.8
Working Capital Requirements	7.0	5.9	5.7
% of net sales	19.0%	16.6%	16.2%
	31.0	33.2	33.5
Long-term Liabilities (*)	7.2	8.0	9.1
Shareholders' Equity	23.9	25.2	24.5
	31.0	33.2	33.5

Robust financial profile

Strong cash management, significant cash position of €15.9M as of September 30, 2018

(*) includes non-cash fair value of warrants of €3.9M in 2016, €0.8M in 2017 and €0M as of Sept. 30, 2018

Company Summary

Innovative minimally-invasive diagnostic and therapeutic tools using ultrasound-based technologies



High Intensity Focused Ultrasound (HIFU)

Robust HIFU Pipeline Extracorporeal ShockWave Lithotripsy (ESWL)

Platform offers a minimally invasive tool for soft tissue ablation, currently approved for use in the treatment of prostate cancer

Opportunities to expand HIFU applications to treat endometriosis, liver cancer and pancreatic cancer Portfolio provides multiple solutions for the destruction of kidney and other urinary stones

edaptms

FANK

Bringing New Horizons to Therapy